{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:31:17Z","timestamp":1784309477882,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High-dose chemotherapy and autologous stem cell transplantation (ASCT) can be associated with adverse events necessitating treatment on the intensive care unit (ICU). Data focusing on patients admitted to the ICU during hospitalization for high-dose chemotherapy and ASCT are scarce. We thus conducted a single-center retrospective analysis comprising 79 individuals who had high-dose chemotherapy and ASCT between 2014 and 2020 and were admitted to the ICU between the initiation of conditioning therapy and day 30 after ASCT. The median age was 57\u00a0years (range: 20\u201382\u00a0years); 38% of patients were female. B-cell non-Hodgkin lymphoma (34%) and plasma cell disorders (28%) were the most common indications for high-dose chemotherapy and ASCT. Sepsis represented the major cause for ICU admission (68%). Twenty-nine percent of patients required mechanical ventilation (MV), 5% had renal replacement therapy, and 44% needed vasopressors. The ICU, hospital, 90-day, and 1-year survival rates were 77.2%, 77.2%, 72.2%, and 60.3%, respectively. Stable disease or disease progression prior to the initiation of high-dose chemotherapy (<jats:italic>p<\/jats:italic>\u2009=\u20090.0028) and MV (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) were associated with an impaired survival. A total of 36 patients died during observation. The most frequent causes of death were the underlying malignancy (44%) and sepsis (39%). Taken together, the present analysis indicates a favorable overall outcome for patients admitted to the ICU during hospitalization for high-dose chemotherapy and ASCT. Thus, this patient group should not be denied admission and treatment on the ICU.<\/jats:p>","DOI":"10.1007\/s00277-022-05028-x","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T09:03:13Z","timestamp":1668675793000},"page":"191-197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysis"],"prefix":"10.1007","volume":"102","author":[{"given":"Jorge","family":"Garcia Borrega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"B\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kochanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Hendrik","family":"Naendrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle","family":"Sieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Holtick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Shimabukuro-Vornhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1927-3514","authenticated-orcid":false,"given":"Dennis A.","family":"Eichenauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Michel","family":"Heger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"5028_CR1","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet 359:2065\u20132071. https:\/\/doi.org\/10.1016\/S0140-6736(02)08938-9","journal-title":"Lancet"},{"key":"5028_CR2","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med 333:1540\u20131545. https:\/\/doi.org\/10.1056\/NEJM199512073332305","journal-title":"N Engl J Med"},{"key":"5028_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01582-5","author":"AJM Ferreri","year":"2022","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E et al (2022) Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. https:\/\/doi.org\/10.1038\/s41375-022-01582-5","journal-title":"Leukemia"},{"key":"5028_CR4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015114","author":"M Brink","year":"2022","unstructured":"Brink M, Meeuwes FO, van der Poel MW et al (2022) Impact of etoposide and ASCT on survival among patients <65 years with stage II-IV PTCL; a population-based cohort study. Blood. https:\/\/doi.org\/10.1182\/blood.2021015114","journal-title":"Blood"},{"key":"5028_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","volume":"4","author":"B Dhakal","year":"2018","unstructured":"Dhakal B, Szabo A, Chhabra S et al (2018) Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction. JAMA Oncol 4:343. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4600","journal-title":"JAMA Oncol"},{"key":"5028_CR6","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1200\/JCO.1999.17.11.3450","volume":"17","author":"C Bokemeyer","year":"1999","unstructured":"Bokemeyer C, Kollmannsberger C, Meisner C et al (1999) First-line high-dose chemotherapy compared with standard-dose PEB\/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 17:3450\u20133456. https:\/\/doi.org\/10.1200\/JCO.1999.17.11.3450","journal-title":"J Clin Oncol"},{"key":"5028_CR7","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.3390\/cancers12061678","volume":"12","author":"P Karagiannis","year":"2020","unstructured":"Karagiannis P, S\u00e4nger L, Alsdorf W et al (2020) Intensive care outcomes of patients after high dose chemotherapy and subsequent autologous stem cell transplantation: a retrospective, single centre analysis. Cancers (Basel) 12:1678. https:\/\/doi.org\/10.3390\/cancers12061678","journal-title":"Cancers (Basel)"},{"key":"5028_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/bmt.2008.336","volume":"43","author":"MA Trinkaus","year":"2009","unstructured":"Trinkaus MA, Lapinsky SE, Crump M et al (2009) Predictors of mortality in patients undergoing autologous hematopoietic cell transplantation admitted to the intensive care unit. Bone Marrow Transplant 43:411\u2013415. https:\/\/doi.org\/10.1038\/bmt.2008.336","journal-title":"Bone Marrow Transplant"},{"key":"5028_CR9","doi-asserted-by":"publisher","first-page":"154077","DOI":"10.1016\/j.jcrc.2022.154077","volume":"71","author":"AP Nassar","year":"2022","unstructured":"Nassar AP, Archanjo LVF, Ranzani OT et al (2022) Characteristics and outcomes of autologous hematopoietic stem cell transplant recipients admitted to intensive care units: a multicenter study. J Crit Care 71:154077. https:\/\/doi.org\/10.1016\/j.jcrc.2022.154077","journal-title":"J Crit Care"},{"key":"5028_CR10","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"key":"5028_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"J-L Vincent","year":"1996","unstructured":"Vincent J-L, Moreno R, Takala J et al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. Intensive Care Med 22:707\u201310. https:\/\/doi.org\/10.1007\/BF01709751","journal-title":"Intensive Care Med"},{"key":"5028_CR12","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1200\/JCO.2012.47.2365","volume":"31","author":"E Azoulay","year":"2013","unstructured":"Azoulay E, Mokart D, P\u00e8ne F et al (2013) Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium\u2014a Groupe de Recherche Respiratoire en R\u00e9animation Onco-H\u00e9matologique Study. J Clin Oncol 31:2810\u20132818. https:\/\/doi.org\/10.1200\/JCO.2012.47.2365","journal-title":"J Clin Oncol"},{"key":"5028_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00277-021-04698-3","volume":"101","author":"J Garcia Borrega","year":"2022","unstructured":"Garcia Borrega J, Heger J-M, Koehler P et al (2022) Allogeneic stem cell transplant recipients admitted to the intensive care unit during the peri-transplant period have unfavorable outcomes\u2014results of a retrospective analysis from a German university hospital. Ann Hematol 101:389\u2013395. https:\/\/doi.org\/10.1007\/s00277-021-04698-3","journal-title":"Ann Hematol"},{"key":"5028_CR14","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1007\/s12630-019-01439-z","volume":"66","author":"M Hamidi","year":"2019","unstructured":"Hamidi M, Gossack-Keenan KL, Ferreyro BL et al (2019) Outcomes of hematopoietic cell transplant recipients requiring invasive mechanical ventilation: a two-centre retrospective cohort study. Can J Anesth Can d\u2019anesth\u00e9sie 66:1450\u20131457. https:\/\/doi.org\/10.1007\/s12630-019-01439-z","journal-title":"Can J Anesth Can d\u2019anesth\u00e9sie"},{"key":"5028_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-56322-0","volume":"9","author":"CS Michel","year":"2019","unstructured":"Michel CS, Teschner D, Schmidtmann I et al (2019) Prognostic factors and outcome of adult allogeneic hematopoietic stem cell transplantation patients admitted to intensive care unit during transplant hospitalization. Sci Rep 9:1\u20137. https:\/\/doi.org\/10.1038\/s41598-019-56322-0","journal-title":"Sci Rep"},{"key":"5028_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjh.17630","volume":"195","author":"CV Maeng","year":"2021","unstructured":"Maeng CV, \u00d8stg\u00e5rd LSG, Christiansen CF, Liu KD (2021) Changes in intensive care unit admission rates, organ support, and mortality in patients with acute myeloid leukaemia over a 12-year period: a Danish nationwide cohort study. Br J Haematol 195:137\u2013140. https:\/\/doi.org\/10.1111\/bjh.17630","journal-title":"Br J Haematol"},{"key":"5028_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/10428194.2016.1195499","volume":"58","author":"S Mayer","year":"2017","unstructured":"Mayer S, Pastores SM, Riedel E et al (2017) Short- and long-term outcomes of adult allogeneic hematopoietic stem cell transplant patients admitted to the intensive care unit in the peritransplant period. Leuk Lymphoma 58:382\u2013390. https:\/\/doi.org\/10.1080\/10428194.2016.1195499","journal-title":"Leuk Lymphoma"},{"key":"5028_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3324\/haematol.2010.031583","volume":"96","author":"P Schellongowski","year":"2011","unstructured":"Schellongowski P, Staudinger T, Kundi M et al (2011) Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience. Haematologica 96:231\u2013237. https:\/\/doi.org\/10.3324\/haematol.2010.031583","journal-title":"Haematologica"},{"key":"5028_CR19","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","volume":"119","author":"CH Moskowitz","year":"2012","unstructured":"Moskowitz CH, Matasar MJ, Zelenetz AD et al (2012) Normalization of pre-ASCT, FDG-PET imaging with second-line, non\u2013cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 119:1665\u20131670. https:\/\/doi.org\/10.1182\/blood-2011-10-388058","journal-title":"Blood"},{"key":"5028_CR20","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","volume":"125","author":"CS Sauter","year":"2015","unstructured":"Sauter CS, Matasar MJ, Meikle J et al (2015) Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood 125:2579\u20132581. https:\/\/doi.org\/10.1182\/blood-2014-10-606939","journal-title":"Blood"},{"key":"5028_CR21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280287","author":"TA Eyre","year":"2022","unstructured":"Eyre TA, Barrington SF, Okosun J et al (2022) Impact of PET-CT status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplant. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2021.280287","journal-title":"Haematologica"},{"key":"5028_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.hemonc.2018.03.003","volume":"11","author":"N Al-Zubaidi","year":"2018","unstructured":"Al-Zubaidi N, Shehada E, Alshabani K et al (2018) Predictors of outcome in patients with hematologic malignancies admitted to the intensive care unit. Hematol Oncol Stem Cell Ther 11:206\u2013218. https:\/\/doi.org\/10.1016\/j.hemonc.2018.03.003","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"5028_CR23","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s001340051350","volume":"26","author":"E Azoulay","year":"2000","unstructured":"Azoulay E, Moreau D, Alberti C et al (2000) Predictors of short-term mortality in critically ill patients with solid malignancies. Intensive Care Med 26:1817\u20131823. https:\/\/doi.org\/10.1007\/s001340051350","journal-title":"Intensive Care Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05028-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-05028-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05028-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T08:49:16Z","timestamp":1672994956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-05028-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["5028"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-05028-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"assertion":[{"value":"28 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given the non-interventional retrospective nature of the study, no ethical approval for its conduct was necessary according to the policy of the ethics committee of the Faculty of Medicine of the University of Cologne. For the same reason, no informed consent had to be obtained from the included patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"JGB received research funding and travel support from Kite\/Gilead; BB received honoraria, research funding, or travel support from Astellas, Celgene, Janssen Cilag, Johnson & Johnson, Kite\/Gilead, MSD, Noscendo, Novartis, Pfizer, Sanofi, and Takeda; MK received honoraria from Astellas, Gilead, MSD, and Pfizer; DAE received honoraria from Sanofi-Genzyme and Takeda; JMH received research funding or travel support from Gilead, Incyte, and Novartis; the other authors declare no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}